Pharma M&A surges on a single day: KKR's $5.7B Integer deal, Curium's $8B Lantheus buy, and AstraZeneca's blocked megamerger signal a restructuring market
Three significant transactions occurred in the pharmaceutical and medtech sectors on August 3, highlighting a split M&A market. While mid-market buyouts such as KKR's acquisition of Integer Holdings and Curium's purchase of Lantheus proceeded, larger megamergers like AstraZeneca's faced obstacles. This suggests a trend towards restructuring within the industry.
- 01KKR acquired Integer Holdings for $5.7 billion.
- 02Curium purchased Lantheus in an $8 billion deal.
- 03AstraZeneca's megamerger attempt was blocked.
Aug 3, 2026